Database : MEDLINE
Search on : Somatostatinoma [Words]
References found : 420 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 42 go to page                         

  1 / 420 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29521948
[Au] Autor:Kilambi R; Singh AN; Das P; Madhusudhan KS; Pal S
[Ad] Address:Department of Gastrointestinal Surgery and Liver Transplantation AIIMS New Delhi, India anandnsingh@gmail.com Department of Pathology AIIMS New Delhi, India Department of Radiodiagnosis AIIMS New Delhi, India Department of Gastrointestinal Surgery and Liver Transplantation AIIMS New Delhi, India.
[Ti] Title:Somatostatinoma Masquerading as Chronic Pancreatitis.
[So] Source:Pancreas;47(4):e19-e20, 2018 Apr.
[Is] ISSN:1536-4828
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Data-Review
[do] DOI:10.1097/MPA.0000000000001011

  2 / 420 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28693748
[Au] Autor:Reynolds R; Marjoniemi V
[Ad] Address:Department of Histopathology, Douglass Hanly Moir Pathology, Sydney, NSW, Australia. Electronic address: rreynolds888@gmail.com.
[Ti] Title:Mixed mucinous adenocarcinoma and somatostatinoma of the ampulla of Vater associated with neurofibromatosis type 1.
[So] Source:Pathology;49(5):553-555, 2017 Aug.
[Is] ISSN:1465-3931
[Cp] Country of publication:England
[La] Language:eng
[Pt] Publication type:LETTER
[Em] Entry month:1707
[Cu] Class update date: 170723
[Lr] Last revision date:170723
[St] Status:In-Data-Review

  3 / 420 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 28639759
[Au] Autor:Rouiller N; Jornayvaz FR
[Ad] Address:Service d'endocrinologie, diabétologie et métabolisme, CHUV, 1011 Lausanne.
[Ti] Title:Diabète sucré secondaire à une endocrinopathie : quand y penser ? [Diabetes mellitus secondary to an endocrine pathology : when to think about it ?]
[So] Source:Rev Med Suisse;13(565):1158-1162, 2017 May 31.
[Is] ISSN:1660-9379
[Cp] Country of publication:Switzerland
[La] Language:fre
[Ab] Abstract:An endocrine disease can be associated with glucose intolerance or diabetes mellitus, and the latter can falsely be considered as type 2 diabetes. Glycemic imbalance can be a direct or indirect consequence of excessive hormone production. Endocrine diseases such as acromegaly, Cushing's syndrome and pheochromocytoma can increase glucose production and cause insulin resistance. Hyperthyroidism, hyperaldosteronism, glucagonoma and somatostatinoma lead to hyperglycemia by other physiopathological mechanisms detailed in this article. When a clinical picture suggests an endocrine disease, several analyses need to be done in order to avoid treatment escalation of diabetes.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1706
[Cu] Class update date: 170622
[Lr] Last revision date:170622
[St] Status:In-Data-Review

  4 / 420 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28608351
[Au] Autor:Aydogan BI; Ünlütürk U; Emral R; Güllü S
[Ad] Address:Ankara University Faculty of Medicine, Department of Endocrinology and Metabolism.
[Ti] Title:Course of Aggressive Somatotroph, Corticotroph and Mammotroph Tumors under Temozolomide; Report of Three Cases and Review of the Literature.
[So] Source:Turk Neurosurg;, 2017 May 07.
[Is] ISSN:1019-5149
[Cp] Country of publication:Turkey
[La] Language:eng
[Ab] Abstract:Treatment of aggressive pituitary tumors may be challenging. Temozolomide (TMZ) is a promising agent when conventional treatment methods fail. We present three patients with aggressive pituitary tumors with atypical morphology, who were resistant to conventional treatments and treated with TMZ. First case had a somatotroph adenoma, second a corticotroph adenoma, and the third a macroprolactinoma. We also reviewed the literature reporting TMZ efficacy in somatotroph, corticotroph and mammotroph tumors of pituitary. TMZ, 150-200 mg/m2 for 5 days in 28 days schedule was given to all patients. Among our patients, even though only the case of macroprolactinoma had a favorable response to TMZ treatment, both radiological and hormonal recurrences occurred 30 months after cessation of TMZ treatment. Then TMZ treatment was applied again. Cases of somatotroph and corticotroph adenomas had progressed under TMZ treatment and patients were lost due to mass effect of the tumor. Review of the literature demonstrated 67.3%, 60% and 26.7% overall response rates to the TMZ treatment in prolactinoma, corticotropinoma and somatostatinoma cases, respectively. There is still need to define response criteria uniformly to TMZ treatment in aggressive pituitary tumors and duration of response should be reported for reliable evaluation of results.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1706
[Cu] Class update date: 170613
[Lr] Last revision date:170613
[St] Status:Publisher
[do] DOI:10.5137/1019-5149.JTN.20216-17.1

  5 / 420 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28336782
[Au] Autor:Janssen I; Chen CC; Zhuang Z; Millo CM; Wolf KI; Ling A; Lin FI; Adams KT; Herscovitch P; Feelders RA; Fojo AT; Taieb D; Kebebew E; Pacak K
[Ad] Address:Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
[Ti] Title:Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes.
[So] Source:J Nucl Med;58(8):1236-1242, 2017 Aug.
[Is] ISSN:1535-5667
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Pheochromocytoma/paraganglioma (PPGL) syndromes associated with polycythemia have previously been described in association with mutations in the von Hippel-Lindau gene. Recently, mutations in the prolyl hydroxylase gene ( ) 1 and 2 and in the hypoxia-inducible factor 2 α ( ) were also found to be associated with multiple and recurrent PPGL. Such patients also presented with PPGL and polycythemia, and later on, some presented with duodenal somatostatinoma. In additional patients presenting with PPGL and polycythemia, no further mutations have been discovered. Because the functional imaging signature of patients with PPGL-polycythemia syndromes is still unknown, and because these tumors (in most patients) are multiple, recurrent, and metastatic, the goal of our study was to assess the optimal imaging approach using 4 different PET radiopharmaceuticals and CT/MRI in these patients. Fourteen patients (10 women, 4 men) with confirmed PPGL and polycythemia prospectively underwent Ga-DOTATATE (13 patients), F-FDG (13 patients), F-fluorodihydroxyphenylalanine ( F-FDOPA) (14 patients), F-fluorodopamine ( F-FDA) (11 patients), and CT/MRI (14 patients). Detection rates of PPGL lesions were compared between all imaging studies and stratified between the underlying mutations. F-FDOPA and F-FDA PET/CT showed similar combined lesion-based detection rates of 98.7% (95% confidence interval [CI], 92.7%-99.8%) and 98.3% (95% CI, 90.9%-99.7%), respectively. The detection rates for Ga-DOTATATE (35.3%; 95% CI, 25.0%-47.2%), F-FDG (42.3; 95% CI, 29.9%-55.8%), and CT/MRI (60.3%; 95% CI, 48.8%-70.7%) were significantly lower ( < 0.01), irrespective of the mutation status. F-FDOPA and F-FDA are superior to F-FDG, Ga-DOTATATE, and CT/MRI and should be the radiopharmaceuticals of choice in this rare group of patients.
[Mh] MeSH terms primary: Multimodal Imaging
Paraganglioma/complications
Polycythemia/complications
Polycythemia/diagnosis
[Mh] MeSH terms secundary: Adolescent
Adult
Child
Female
Humans
Male
Middle Aged
Young Adult
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1708
[Cu] Class update date: 170825
[Lr] Last revision date:170825
[Js] Journal subset:IM
[Da] Date of entry for processing:170325
[St] Status:MEDLINE
[do] DOI:10.2967/jnumed.116.187690

  6 / 420 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 27679736
[Au] Autor:Därr R; Nambuba J; Del Rivero J; Janssen I; Merino M; Todorovic M; Balint B; Jochmanova I; Prchal JT; Lechan RM; Tischler AS; Popovic V; Miljic D; Adams KT; Prall FR; Ling A; Golomb MR; Ferguson M; Nilubol N; Chen CC; Chew E; Taïeb D; Stratakis CA; Fojo T; Yang C; Kebebew E; Zhuang Z; Pacak K
[Ad] Address:Section on Medical NeuroendocrinologyEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
[Ti] Title:Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome.
[So] Source:Endocr Relat Cancer;23(12):899-908, 2016 Dec.
[Is] ISSN:1479-6821
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Worldwide, the syndromes of paraganglioma (PGL), somatostatinoma (SOM) and early childhood polycythemia are described in only a few patients with somatic mutations in the hypoxia-inducible factor 2 alpha (HIF2A). This study provides detailed information about the clinical aspects and course of 7 patients with this syndrome and brings into perspective these experiences with the pertinent literature. Six females and one male presented at a median age of 28 years (range 11-46). Two were found to have HIF2A somatic mosaicism. No relatives were affected. All patients were diagnosed with polycythemia before age 8 and before PGL/SOM developed. PGLs were found at a median age of 17 years (range 8-38) and SOMs at 29 years (range 22-38). PGLs were multiple, recurrent and metastatic in 100, 100 and 29% of all cases, and SOMs in 40, 40 and 60%, respectively. All PGLs were primarily norepinephrine-producing. All patients had abnormal ophthalmologic findings and those with SOMs had gallbladder disease. Computed tomography (CT) and magnetic resonance imaging revealed cystic lesions at multiple sites and hemangiomas in 4 patients (57%), previously thought to be pathognomonic for von Hippel-Lindau disease. The most accurate radiopharmaceutical to detect PGL appeared to be [ F]-fluorodihydroxyphenylalanine ([ F]-FDOPA). Therefore, [ F]-FDOPA PET/CT, not [ Ga]-(DOTA)-[Tyr3]-octreotate ([ Ga]-DOTATATE) PET/CT is recommended for tumor localization and aftercare in this syndrome. The long-term prognosis of the syndrome is unknown. However, to date no deaths occurred after 6 years follow-up. Physicians should be aware of this unique syndrome and its diagnostic and therapeutic challenges.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1609
[Cu] Class update date: 170224
[Lr] Last revision date:170224
[St] Status:In-Process

  7 / 420 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27584907
[Au] Autor:Killingsworth MC; Bobryshev YV
[Ad] Address:South Western Sydney Clinical School, Faculty of Medicine, University of New South Wales Australia; School of Medicine, Western Sydney University; Correlative Microscopy Group, Ingham Institute for Applied Medical Research; Electron Microscopy Laboratory, Department of Anatomical Pathology, Sydney South West Pathology Service, New South Wales Health Pathology; murray.killingsworth@sswahs.nsw.gov.au.
[Ti] Title:Correlative Light- and Electron Microscopy Using Quantum Dot Nanoparticles.
[So] Source:J Vis Exp;(114), 2016 Aug 07.
[Is] ISSN:1940-087X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:A method is described whereby quantum dot (QD) nanoparticles can be used for correlative immunocytochemical studies of human pathology tissue using widefield fluorescence light microscopy and transmission electron microscopy (TEM). To demonstrate the protocol we have immunolabeled ultrathin epoxy sections of human somatostatinoma tumor using a primary antibody to somatostatin, followed by a biotinylated secondary antibody and visualization with streptavidin conjugated 585 nm cadmium-selenium (CdSe) quantum dots (QDs). The sections are mounted on a TEM specimen grid then placed on a glass slide for observation by widefield fluorescence light microscopy. Light microscopy reveals 585 nm QD labeling as bright orange fluorescence forming a granular pattern within the tumor cell cytoplasm. At low to mid-range magnification by light microscopy the labeling pattern can be easily recognized and the level of non-specific or background labeling assessed. This is a critical step for subsequent interpretation of the immunolabeling pattern by TEM and evaluation of the morphological context. The same section is then blotted dry and viewed by TEM. QD probes are seen to be attached to amorphous material contained in individual secretory granules. Images are acquired from the same region of interest (ROI) seen by light microscopy for correlative analysis. Corresponding images from each modality may then be blended to overlay fluorescence data on TEM ultrastructure of the corresponding region.
[Mh] MeSH terms primary: Microscopy, Electron, Transmission/methods
Nanoparticles/ultrastructure
Quantum Dots/ultrastructure
Selenium Compounds/chemistry
[Mh] MeSH terms secundary: Fluorescence
Humans
Microscopy, Fluorescence/methods
[Pt] Publication type:JOURNAL ARTICLE; VIDEO-AUDIO MEDIA
[Nm] Name of substance:0 (Selenium Compounds)
[Em] Entry month:1707
[Cu] Class update date: 170719
[Lr] Last revision date:170719
[Js] Journal subset:IM
[Da] Date of entry for processing:160902
[St] Status:MEDLINE
[do] DOI:10.3791/54307

  8 / 420 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27510677
[Au] Autor:Kumar T; Gupta B; Das P; Jain D; Jain HA; Madhusudhan KS; Dash NR; Gupta SD
[Ad] Address:Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
[Ti] Title:Combined presence of multiple gastrointestinal stromal tumors along with duodenal submucosal somatostatinoma in a patient with neurofibromatosis type 1.
[So] Source:Indian J Pathol Microbiol;59(3):359-61, 2016 Jul-Sep.
[Is] ISSN:0974-5130
[Cp] Country of publication:India
[La] Language:eng
[Ab] Abstract:Neurofibromatosis type-1 (NF-1) is an autosomal dominant disorder, with increased risk of developing benign and malignant tumors of the gastrointestinal tract (GIT). However, the synchronous presence of multiple GIT stromal tumors and duodenal submucosal somatostatinoma, like in this 50-year-old female NF-1 patient, is very rare. She presented with hematemesis, malena, along with multiple neurofibromas all over the body. Thorough radiological and peroperative work-up revealed multiple ulcerated submucosal and serosal nodules in the proximal small intestine. Histological work-up revealed diagnosis of a duodenal submucosal somatostatinoma with multifocal serosal gastrointestinal stromal tumors. This case is being reported to highlight the rare coincidence of multiple GIT tumors in an NF-1 patient.
[Mh] MeSH terms primary: Gastrointestinal Stromal Tumors/complications
Gastrointestinal Stromal Tumors/diagnosis
Neurofibromatosis 1/complications
Neurofibromatosis 1/diagnosis
Somatostatinoma/complications
Somatostatinoma/diagnosis
[Mh] MeSH terms secundary: Biomarkers, Tumor/analysis
Female
Gastrointestinal Stromal Tumors/diagnostic imaging
Gastrointestinal Stromal Tumors/pathology
Hematemesis/etiology
Histocytochemistry
Humans
Immunohistochemistry
Intestine, Small/pathology
Melena/etiology
Microscopy
Middle Aged
Neurofibromatosis 1/pathology
Radiography, Abdominal
Somatostatin/analysis
Somatostatinoma/diagnostic imaging
Somatostatinoma/pathology
Synaptophysin/analysis
Tomography, X-Ray Computed
[Pt] Publication type:CASE REPORTS
[Nm] Name of substance:0 (Biomarkers, Tumor); 0 (Synaptophysin); 51110-01-1 (Somatostatin)
[Em] Entry month:1703
[Cu] Class update date: 170313
[Lr] Last revision date:170313
[Js] Journal subset:IM
[Da] Date of entry for processing:160812
[St] Status:MEDLINE
[do] DOI:10.4103/0377-4929.188123

  9 / 420 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27404266
[Au] Autor:Parbhu SK; Adler DG
[Ad] Address:a Department of Internal Medicine, Division of Gastroenterology and Hepatology , University of Utah School of Medicine, Huntsman Cancer Center , Salt Lake City , Utah , USA.
[Ti] Title:Pancreatic neuroendocrine tumors: contemporary diagnosis and management.
[So] Source:Hosp Pract (1995);44(3):109-19, 2016 Aug.
[Is] ISSN:2154-8331
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Pancreatic neuroendocrine tumors (PNETs) are neoplasms that arise from the hormone producing cells of the islets of Langerhans, also known as pancreatic islet cells. PNETs are considered a subgroup of neuroendocrine tumors, and have unique biology, natural history and clinical management. These tumors are classified as 'functional' or 'non-functional' depending on whether they release peptide hormones that produce specific hormone- related symptoms, usually in established patterns based on tumor subtype. This manuscript will review pancreatic neuroendocrine tumor subtypes, syndromes, diagnosis, and clinical management.
[Mh] MeSH terms primary: Neuroendocrine Tumors/diagnosis
Neuroendocrine Tumors/therapy
Pancreatic Neoplasms/diagnosis
Pancreatic Neoplasms/therapy
[Mh] MeSH terms secundary: Carcinoma, Islet Cell/physiopathology
Carcinoma, Islet Cell/therapy
Continental Population Groups
Humans
Insulinoma/physiopathology
Insulinoma/therapy
Islets of Langerhans
Multiple Endocrine Neoplasia Type 1/physiopathology
Multiple Endocrine Neoplasia Type 1/therapy
Neoplasm Grading
Neoplasm Staging
Neuroendocrine Tumors/physiopathology
Pancreatic Hormones
Pancreatic Neoplasms/physiopathology
Peptide Hormones
Sex Factors
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Pancreatic Hormones); 0 (Peptide Hormones)
[Em] Entry month:1702
[Cu] Class update date: 170206
[Lr] Last revision date:170206
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:160713
[St] Status:MEDLINE
[do] DOI:10.1080/21548331.2016.1210474

  10 / 420 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 27078626
[Au] Autor:Jara Letelier DI; Bonotto ML; Ardengh JC
[Ad] Address:Gastroenterology Section and Endoscopy Unit, Hospital del Salvador and Faculty of Medicine, Universidad de Chile, Santiago, Chile.
[Ti] Title:Somatostatinoma of the minor duodenal papilla associated with pancreas divisum treated by endoscopic papillectomy.
[So] Source:Endoscopy;48 Suppl 1:E135-7, 2016.
[Is] ISSN:1438-8812
[Cp] Country of publication:Germany
[La] Language:eng
[Mh] MeSH terms primary: Endoscopy, Digestive System/methods
Endosonography/methods
Image-Guided Biopsy/methods
Pancreatic Ducts
Pancreatic Neoplasms
Somatostatinoma
Sphincterotomy, Endoscopic/methods
[Mh] MeSH terms secundary: Female
Humans
Magnetic Resonance Imaging/methods
Middle Aged
Pancreatic Ducts/diagnostic imaging
Pancreatic Ducts/pathology
Pancreatic Neoplasms/pathology
Pancreatic Neoplasms/physiopathology
Pancreatic Neoplasms/surgery
Somatostatinoma/pathology
Somatostatinoma/physiopathology
Somatostatinoma/surgery
Tomography, X-Ray Computed/methods
Treatment Outcome
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE; VIDEO-AUDIO MEDIA
[Em] Entry month:1701
[Cu] Class update date: 170104
[Lr] Last revision date:170104
[Js] Journal subset:IM
[Da] Date of entry for processing:160415
[St] Status:MEDLINE
[do] DOI:10.1055/s-0042-104928


page 1 of 42 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information